Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ghyslain Mombo-NgomaPeter G Kremsner

Abstract

Fosmidomycin-piperaquine is being developed as nonartemisinin-based combination therapy to meet the challenge of emerging artemisinin resistance. The study was a phase 2, single-arm, proof-of-concept study of the efficacy, tolerability, and safety of fosmidomycin-piperaquine for the treatment of uncomplicated Plasmodium falciparum monoinfection in Gabon. Adults and children of both sexes with initial parasite counts between 1000 and 150000/µL received oral treatment with fosmidomycin (twice daily doses of 30 mg/kg) and piperaquine (once daily dose of 16 mg/kg) for 3 days and followed-up for 63 days. The primary efficacy endpoint was the per-protocol polymerase chain reaction (PCR)-corrected day 28 adequate clinical and parasitological response (ACPR). One hundred patients were enrolled. The PCR-corrected day 28 ACPR rate was 83/83, or 100% (95% confidence interval, 96-100). Fourteen patients had asexual parasitaemia between day 28 and day 63; all were typed by PCR as new infections. Fosmidomycin-piperaquine therapy led to rapid parasite clearance (median, 36 hours; interquartile range [IQR], 6-60) and fever clearance time (median, 12 hours; IQR, 6-48). The electrocardiogram assessments showed 2 patients with prolonged QT interv...Continue Reading

References

May 7, 2002·The Journal of Infectious Diseases·Kesinee ChotivanichNicholas J White
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Jochen WiesnerHassan Jomaa
Dec 21, 2002·Lancet·Michel A MissinouPeter G Kremsner
Jan 21, 2003·Bulletin of Experimental Biology and Medicine·Nguen Van HaS A Rabinovich
Oct 13, 2004·The Journal of Infectious Diseases·Steffen BorrmannPeter G Kremsner
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Steffen BorrmannPeter G Kremsner
Jan 1, 2007·Wiener klinische Wochenschrift·Michael RamharterPeter G Kremsner
Aug 1, 2015·Future Microbiology·Jose Francisco FernandesMartin Peter Grobusch
Jun 5, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Thomas M AtkinsonEthan Basch
Jun 23, 2016·The New England Journal of Medicine·Didier MénardUNKNOWN KARMA Consortium
Feb 15, 2017·Antimicrobial Agents and Chemotherapy·Pattaraporn VanachayangkulDavid Saunders

❮ Previous
Next ❯

Citations

Dec 24, 2018·Expert Opinion on Investigational Drugs·Juliana Boex MengueAndrea Kreidenweiss
Nov 30, 2019·Future Medicinal Chemistry·Ishan WadiAbhinav Sinha
Sep 24, 2019·Natural Product Reports·Raúl G Saraiva, George Dimopoulos
May 29, 2018·Drugs·Elizabeth A Ashley, Aung Pyae Phyo
Jan 2, 2021·Malaria Journal·Bui Van LongThirumalaisamy P Velavan
Feb 7, 2021·Parasitology International·Kazuro Shiomi
Dec 12, 2020·European Journal of Medicinal Chemistry·Sharyu Kesharwani, Sandeep Sundriyal
Jul 29, 2021·Malaria Journal·Patrick B Memvanga, Christian I Nkanga
Oct 23, 2018·ACS Medicinal Chemistry Letters·Charlotte CourtensSerge Van Calenbergh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

Antimicrobial Agents and Chemotherapy
Bertrand LellPeter G Kremsner
© 2022 Meta ULC. All rights reserved